Plasma osteopontin level in chronic liver disease and hepatocellular carcinoma

Hepatitis Monthly

Volumn 15, Issue 9, 2015, Pages

  Fouad, Shawky Abdelhamid ^a   Mohamed, Nagwa Abdel Ghaffar ^b   Fawzy, Mary Wadie ^a   Moustafa, Doaa Ali ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Fatty liver; Hepatocellular carcinoma; Osteopontin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; CREATININE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; OSTEOPONTIN; SERUM ALBUMIN; UREA; VIRUS RNA;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CHRONIC HEPATITIS C; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS C VIRUS; HUMAN; IMMUNOASSAY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROTHROMBIN TIME; SENSITIVITY AND SPECIFICITY;

EID: 84949324738     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.30753     Document Type: Article

References (32)

1. Nagoshi S. Osteopontin: Versatile modulator of liver diseases. Hepatol Res. 2014;44(1):22–30.
2. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000;287(5454):860–4.
3. Suzuki H, Amizuka N, Oda K, Li M, Yoshie H, Ohshima H, et al. Histological evidence of the altered distribution of osteocytes and bone matrix synthesis in klotho-deficient mice. Arch Histol Cytol. 2005;68(5):371–81.
4. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993;7(15):1475–82.
5. Huang W, Zhu G, Huang M, Lou G, Liu Y, Wang S. Plasma osteopontin concentration correlates with the severity of hepatic fibrosis and inflammation in HCV-infected subjects. Clin Chim Acta. 2010;411(9-10):675–8.
6. Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut. 2007;56(6):782–9.
7. Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH, et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology. 2011;53(1):106–15.
8. Ranjbar Kermani F, Sharifi Z, Ferdowsian F, Paz Z, Tavassoli F. The Usefulness of Anti-HCV Signal to Cut-off Ratio in Predicting Viremia in Anti-HCV in Patients With Hepatitis C Virus Infection. Jundishapur J Microbiol. 2015;8(4):e17841.
9. Moini M, Ziyaeyan M, Aghaei S, Sagheb MM, Taghavi SA, Moeini M, et al. Hepatitis C virus (HCV) Infection Rate among Seronegative Hemodialysis Patients Screened by Two Methods; HCV Core Antigen and Polymerase Chain Reaction. Hepat Mon. 2013;13(6):e9147.
10. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153–6.
11. Charlton M. Hepatitis C infection in liver transplantation. Am J Transplant. 2001;1(3):197–203.
12. El-Zanaty F, Wany A, Macro International.. Egypt Demographic and Health Survey 2008.Cairo: Egyptian: Ministry of Health; 2009.
13. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17(2):107–15.
14. Bruix J, Sherman M, Practice Guidelines Committee AAFTSOLD. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–36.
15. Ostheimer C, Bache M, Guttler A, Reese T, Vordermark D. Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer. BMC Cancer. 2014;14:858.
16. Fouad SA, Elsaaid NH, Mohamed NA, Abutaleb OM. Diagnostic Value of Serum Level of Soluble Tumor Necrosis Factor Receptor IIalpha in Egyptian Patients With Chronic Hepatitis C Virus Infection and Hepatocellular Carcinoma. Hepat Mon. 2014;14(9):e19346.
17. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366(3):216–24.
18. Colli A, Fraquelli M, Conte D. Alpha-fetoprotein and hepatocellular carcinoma. Am J Gastroenterol. 2006;101(8):1939.
19. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology. 2012;55(2):483–90.
20. Matsui A, Mochida S, Ohno A, Nagoshi S, Hirose T, Fujiwara K. Plasma osteopontin levels in patients with fulminant hepatitis. Hepatol Res. 2004;29(4):202–6.
21. Wang JH, Changchien CS, Hu TH, Lee CM, Kee KM, Lin CY, et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. Eur J Cancer. 2008;44(7):1000–6.
22. Kim J, Ki SS, Lee SD, Han CJ, Kim YC, Park SH, et al. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol. 2006;101(9):2051–9.
23. Ramaiah SK, Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci. 2008;103(1):4–13.
24. Taketa K, Okada S, Win N, Hlaing NK, Wind KM. Evaluation of tumor markers for the detection of hepatocellular carcinoma in Yangon General Hospital, Myanmar. Acta Med Okayama. 2002;56(6):317–20.
25. Gad A, Tanaka E, Matsumoto A, El-Hamid Serwah A, Attia F, Hassan A, et al. Ethnicity affects the diagnostic validity of alpha-fetoprotein in hepatocellular carcinoma. Asia-Pacific J Clin Oncol. 2005;1(2-3):64–70.
26. Zhao L, Li T, Wang Y, Pan Y, Ning H, Hui X, et al. Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection. Int J Clin Pract. 2008;62(7):1056–62.
27. Zhang CH, Xu GL, Jia WD, Ge YS, Li JS, Ma JL, et al. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer. 2012;130(11):2685–92.
28. Yilmaz Y, Ozturk O, Alahdab YO, Senates E, Colak Y, Doganay HL, et al. Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. Dig Liver Dis. 2013;45(1):58–62.
29. El-Din Bessa SS, Elwan NM, Suliman GA, El-Shourbagy SH. Clinical significance of plasma osteopontin level in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma. Arch Med Res. 2010;41(7):541–7.
30. Abu El Makarem MA, Abdel-Aleem A, Ali A, Saber R, Shatat M, Rahem DA, et al. Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Ann Hepatol. 2011;10(3):296–305.
31. Nabih MI, Aref WM, Fathy MM. Significance of plasma osteopontin in diagnosis of hepatitis C virus-related hepatocellular carcinoma. Arab J Gastroenterol. 2014;15(3-4):103–7.
32. Keddeas MW, Abo-shady RA. Evaluation of plasma osteopontin level as a biomarker for hepatocellular carcinoma in Egyptian patients. Egypt Liver J. 2011;1(1):38–42.